6 research outputs found
Advances in pulmonary hypertension diagnosis and risk stratification.
editorial reviewedPulmonary hypertension (PH) is a common clinical condition linked to chronic cardiopulmonary illnesses. It must be distinguished from pulmonary arterial hypertension (PAH), a rare disease characterized by a specific involvement of the pulmonary arterial bed. An early diagnosis and accurate classification by a multidisciplinary team are necessary for a multimodal and individualized therapy approach. This article aims to provide a summary of the most recent ESC/ERS recommendations published in 2022.L’hypertension pulmonaire (HTP) est une entité clinique fréquemment retrouvée chez les patients atteints d’affections cardio-pulmonaires chroniques. Elle est à différentier de l’hypertension artérielle pulmonaire (HTAP) qui est, quant à elle, une maladie rare caractérisée par une atteinte spécifique du lit artériel pulmonaire. Une identification précoce et une classification correcte, en équipe pluridisciplinaire, sont primordiales pour une prise en charge thérapeutique multimodale et personnalisée. Cet article a pour but de résumer, de façon pratique, les dernières recommandations des sociétés européennes de cardiologie (ESC) et de pneumologie (ERS) publiées en 2022
Clinical experience in anti-synthetase syndrome: a monocentric retrospective analytical study.
OBJECTIVES: Anti-synthetase syndrome (ASS) is a rare autoimmune disorder combining
autoantibodies and specific clinical manifestations. One of the particularities of
ASS is the pleiomorphic radiological presentation seen at the initial work-up.
Evaluating treatment response can also be challenging and requires specific
clinical, functional, biological and radiological monitoring. For these reasons, it
is fundamental to identify specific radiological and clinical features of ASS for
improved diagnosis and therapeutic approaches.METHODS: We retrospectively studied
all patients suffering from ASS in the CHU of Liège from 2008 to 2019. We analysed
the clinical features, pulmonary function tests (PFTs), computed tomography (CT),
and longitudinal evolution with regard to patient treatment.RESULTS: In the whole
cohort of 30 patients, we identified 19 with anti-JO1 antibodies, 5 with anti-PL12
antibodies and 6 with anti-PL7 antibodies. The sex ratio was slightly in favour of
males. Interestingly, PL-12 syndrome was more likely to be present in younger
patients than those associated with other antibodies. Overall, 77% of the overall
cohort exhibited specific pulmonary involvement without any significant difference
with regard to the severity assessed by PFT at diagnosis. In contrast, the
radiological presentation was pleomorphic for anti-JO1 syndrome, and anti-PL12
syndrome exhibited mainly ground-glass opacities (GGOs) and reticular abnormalities,
while those with anti-PL7 antibodies showed reticulations and bronchiectasis.
Longitudinal CT analysis mainly showed a reduction in consolidations and GGOs with
specific therapies.CONCLUSION: In our single-centre retrospective study, we found
different profiles for different autoantibodies according to age and radiological
appearance